Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL

[1]  H. Knowles,et al.  Ewing sarcoma cells express RANKL and support osteoclastogenesis , 2011, The Journal of pathology.

[2]  M. Heymann,et al.  Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: Preclinical studies and case report of an osteosarcoma pediatric patient , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  O. Delattre,et al.  Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. , 2010, Cancer research.

[4]  D. Scherman,et al.  Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models , 2010, Cancer Gene Therapy.

[5]  M. Dimopoulos,et al.  RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases , 2009, Expert opinion on biological therapy.

[6]  P. Kostenuik,et al.  Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  E. Miot-Noirault,et al.  Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. , 2009, Cancer research.

[8]  B. Pitard,et al.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.

[9]  N. Athanasou,et al.  Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma , 2007, British Journal of Cancer.

[10]  E. Steliarova-Foucher,et al.  Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. , 2006, European journal of cancer.

[11]  E. Steliarova-Foucher,et al.  Quality, comparability and methods of analysis of data on childhood cancer in Europe (1978-1997): report from the Automated Childhood Cancer Information System project. , 2006, European journal of cancer.

[12]  S. M. Sims,et al.  Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.

[13]  B. Pitard,et al.  Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles. , 2005, Human gene therapy.

[14]  D. Escande,et al.  Nonionic amphiphilic block copolymers promote gene transfer to the lung. , 2005, Human gene therapy.

[15]  J. Thiery,et al.  Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. , 2005, Bone.

[16]  S. Théoleyre,et al.  The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.

[17]  M. Padrines,et al.  RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. , 2004, Biochimica et biophysica acta.

[18]  Colin R Dunstan,et al.  A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  N. Kanomata,et al.  Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. , 2003, Cancer research.

[20]  Y. Iwamoto,et al.  Identification of p21 WAF1/CIP1 as a Direct Target of EWS-Fli1 Oncogenic Fusion Protein* , 2003, The Journal of Biological Chemistry.

[21]  P. Croucher,et al.  Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. , 2003, Cancer research.

[22]  P. Croucher,et al.  Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. , 2003, Cancer research.

[23]  R. Kitazawa,et al.  RANK ligand is a prerequisite for cancer‐associated osteolytic lesions , 2002, The Journal of pathology.

[24]  D. Escande,et al.  A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles. , 2002, Human gene therapy.

[25]  F. Hamdy,et al.  Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. , 2002, Cancer research.

[26]  I. Holen,et al.  Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. , 2001, Blood.

[27]  J. Goldblum,et al.  Expression of Fli-1, a Nuclear Transcription Factor, Distinguishes Vascular Neoplasms From Potential Mimics , 2001, The American journal of surgical pathology.

[28]  L. Hofbauer,et al.  Receptor activator of nuclear factor‐κB ligand and osteoprotegerin , 2001 .

[29]  P. Kostenuik,et al.  Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. , 2001, Cancer research.

[30]  O. Delattre,et al.  Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression , 2001, Oncogene.

[31]  P. Mantyh,et al.  Osteoprotegerin diminishes advanced bone cancer pain. , 2001, Cancer research.

[32]  L. Hofbauer,et al.  Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology , 2001, Journal of Molecular Medicine.

[33]  D. Lacey,et al.  Osteoprotegerin inhibits tumor‐induced osteoclastogenesis and bone tumor growth in osteopetrotic mice , 2000, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[34]  J. Mönkkönen,et al.  Cellular and molecular mechanisms of action of bisphosphonates , 2000, Cancer.

[35]  H. Jürgens,et al.  Deskriptive Epidemiologie der Ewing-Tumoren - Analysen der deutschen Patienten von (EI) CESS 1980-1997* , 1999 .

[36]  K Yano,et al.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.

[37]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[38]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[39]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[40]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[41]  C. Denny,et al.  Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Santamaría,et al.  The neuroectodermal tumor of bone , 1984, The American journal of surgical pathology.

[43]  J. Ewing.  Diffuse endothelioma of bone , 1972 .

[44]  A. Cabrera,et al.  EWING'S SARCOMA. , 1964, Surgery, gynecology & obstetrics.

[45]  G. Moriceau,et al.  Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. , 2010, Biochimica et biophysica acta.

[46]  C. Albert,et al.  Classics in oncology , 2006 .

[47]  D. Escande,et al.  Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. , 2004, Nucleic acids research.

[48]  D. Heymann,et al.  Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. , 2003, The American journal of pathology.

[49]  J. Chirgwin,et al.  Molecular mechanisms of tumor-bone interactions in osteolytic metastases. , 2000, Critical reviews in eukaryotic gene expression.

[50]  H. Hense,et al.  [Descriptive epidemiology of Ewing's tumor--analysis of German patients from (EI)CESS 1980-1997]. , 1999, Klinische Padiatrie.

[51]  J. Ewing.  Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921. , 1972, CA: a cancer journal for clinicians.

[52]  T. Martin,et al.  Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation* , 2022 .